Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

Pluripotent patents make prime time: an analysis of the emerging landscape

Nature Biotechnology volume 28, pages 557–559 (2010)Cite this article

Subjects

A Corrigendum to this article was published on 13 October 2010

This article has been updated

An examination of three patents in the fast-moving iPS space may help determine their ultimate value.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 13 October 2010

    In the version of this article initially published, the authors state: “The patents have been cross-licensed, protecting against unlicensed use of either method. Both the Sakurada and Yamanaka patents are part of the portfolio held by iPierian, a company recently formed by the merger of iZumi Bio, a San Francisco Bay Area biotech and Boston-based Pierian.” This statement is incorrect. The Yamanaka patent (owned by Kyoto University) is not licensed to iPierian. The Sakurada patent (owned by iPierian) is not licensed to Kyoto University. The error has been corrected in the HTML and PDF versions of the article.

References

  1. Takahashi, K. et al. Cell 131, 861–872 (2007).

    Article  CAS  PubMed  Google Scholar 

  2. Yu, J. et al. Science 318, 1917–1920 (2007).

    Article  CAS  PubMed  Google Scholar 

  3. Park, I. et al. Cell 134, 877–886 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yamanaka, S. Japan patent JP 2008–131577 (2008).

  5. Sakurada, K. et al. UK patent GB2450603 (2010).

  6. Jaenisch, R. et al. US patent 7,682,828 (20104).

  7. 35 USC § 112.

  8. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1366 (Fed. Cir. 2010) (en banc).

  9. In re Wands, 858 F.2d 731 (Fed. Cir. 1988).

  10. Regents of the University of California v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997).

  11. USPTO. Manual of Patent Examining Procedure §§ 2131.02, 2144.08, edn. 8th (US Patent and Trademark Office; 2008).

  12. Evans, M.J. & Kaufman, M.H. Nature 292, 154–156 (1981).

    Article  CAS  PubMed  Google Scholar 

  13. Vrtovec, K. & Scott, C.T. Nat. Biotechnol. 26, 393–395 (2008).

    Article  CAS  PubMed  Google Scholar 

  14. USPTO Board of Patent Appeals and Interferences, Foundation of Taxpayer & Consumer Rights v. Patent of WARF, Appeal 2010-001854, Patent 7,029,913 (April 28, 2010).

  15. Jaenisch, R. et al. United States Patent Application No. 12/703,061 (filed 2010).

  16. Jaenisch, R. et al. United States Patent Application No. 12/703,015 (filed 2010).

  17. USPTO Requirement for Restriction/Election in US Patent Application No. 10/997,146 (mailed May 24, 2006).

  18. Yu, J. & Thomson, J.A. Genes Dev. 22, 1987–1997 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. In re Kubin, 561 F.3d 1351 (Fed. Cir. 2009).

  20. Zhou, H. et al. Cell Stem Cell 4, 381–384 (2009).

    CAS  PubMed  Google Scholar 

  21. Normile, D. Science Insider (February 8, 2010). http://news.sciencemag.org/scienceinsider/2010/02/landmark-plurip.html

Download references

Acknowledgements

Thanks to the Stem Cell Network (Canada) for their generous funding. A special thanks to E. Chiao for his extremely helpful insights.

Author information

Authors and Affiliations

  1. Brenda M. Simon and Charles E. Murdoch are at the Stanford University Center for Law and the Biosciences Stanford, California, USA.,

    Brenda M Simon, Charles E Murdoch & Christopher T Scott

  2. Charles E. Murdoch and Christopher T. Scott are at the Stanford University Program on Stem Cells in Society, Stanford, California, USA.,

    Charles E Murdoch

Authors
  1. Brenda M Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles E Murdoch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher T Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Brenda M Simon or Christopher T Scott.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simon, B., Murdoch, C. & Scott, C. Pluripotent patents make prime time: an analysis of the emerging landscape. Nat Biotechnol 28, 557–559 (2010). https://doi.org/10.1038/nbt0610-557

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0610-557

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research